EUVIMEDEUVIMED entdecken
Crossref

Establishment of a BRAF V595E ‐mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer

Masanori Kobayashi iD, Moe Onozawa, Shiho Watanabe, Tomokazu Nagashima, Kyoichi Tamura, Yoshiaki Kubo, Akiko Ikeda, Kazuhiko Ochiai iD, Masaki Michishita iD, Makoto Bonkobara iD, Masato Kobayashi, Tatsuya Hori und 1 weitere

Veterinary and Comparative Oncology · 2023

DOI: 10.1111/vco.12879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Masanori Kobayashi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Reproduction, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan. Hauptthemen laut MEDLINE: Dog Diseases, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: KAKENHI scientific research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canine prostate cancer (cPCa) is a malignant neoplasm with no effective therapy. The BRAF V595E mutation, corresponding to the human BRAF V600E mutation, is found frequently in cPCa. Activating BRAF mutations are recognized as oncogenic drivers, and blockade of MAPK/ERK phosphorylation may be an effective therapeutic target against BRAF‐mutated tumours. The aim of this study was to establish a novel cPCa cell line and to clarify the antitumor effects of MEK inhibitors on cPCa in vitro and in vivo. We established the novel CHP‐2 cPCa cell line that was derived from the prostatic tissue of a cPCa patient. Sequencing of the canine BRAF gene in two cPCa cell lines revealed the presence of the BRAF V595E mutation. MEK inhibitors (trametinib, cobimetinib and mirdametinib) strongly suppressed cell proliferation in vitro, and trametinib showed the highest efficacy against cPCa cells with minimal cytotoxicity to non‐cancer COPK cells. Furthermore, we orally administered 0.3 or 1.0 mg/kg trametinib to CHP‐2 xenografted mice and examined its antitumor effects in vivo. Trametinib reduced tumour volume, decreased phosphorylated ERK levels, and lowered Ki‐67 expression in xenografts in a dose‐dependent manner. Although no clear adverse events were observed with administration, trametinib‐treated xenografts showed osteogenesis that was independent of dosage. Our results indicate that trametinib induces cell cycle arrest by inhibiting ERK activation, resulting in cPCa tumour regression in a dose‐dependent manner. MEK inhibitors, in addition to BRAF inhibitors, may be a targeted agent option for cPCa with the BRAF V595E mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesProstatic NeoplasmsMaleHumansAnimalsDogsMiceProto-Oncogene Proteins B-rafCell Line, TumorProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesMutation

Stichwörter der Autor:innen

BRAFMEK inhibitorcaninephosphorylationprostate cancer

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesBRAF protein, human

Autor:innen und Institutionen

  • Laboratory of Reproduction, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan.
  • Laboratory of Veterinary Pathology, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan.
  • Laboratory of Veterinary Clinical Pathology, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan.
  • Veterinary Medical Teaching Hospital, Nippon Veterinary and Life Science University, Tokyo, Japan.
  • Laboratory of Veterinary Hygiene, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan.
  • Japan Institute of Small Animal Reproduction (Bio Art), Tokyo, Japan.

ORCID-Profile: Masanori Kobayashi, Kazuhiko Ochiai, Masaki Michishita, Makoto Bonkobara

Förderung

  • KAKENHI scientific research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Kobayashi, M., Onozawa, M., Watanabe, S., Nagashima, T., Tamura, K., Kubo, Y., Ikeda, A., Ochiai, K., Michishita, M., Bonkobara, M., Kobayashi, M., Hori, T., & Kawakami, E. (2023). Establishment of a BRAF V595E ‐mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12879

Vancouver

Kobayashi M, Onozawa M, Watanabe S, Nagashima T, Tamura K, Kubo Y, et al. Establishment of a BRAF V595E ‐mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12879

BibTeX
@article{Kobayashi2023,
  author = {Kobayashi, Masanori and Onozawa, Moe and Watanabe, Shiho and Nagashima, Tomokazu and Tamura, Kyoichi and Kubo, Yoshiaki and Ikeda, Akiko and Ochiai, Kazuhiko and Michishita, Masaki and Bonkobara, Makoto and Kobayashi, Masato and Hori, Tatsuya and Kawakami, Eiichi},
  title = {Establishment of a BRAF V595E ‐mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer},
  journal = {Veterinary and Comparative Oncology},
  year = {2023},
  doi = {10.1111/vco.12879}
}
Kostenlos starten →